A detailed history of Barclays PLC transactions in Biote Corp. stock. As of the latest transaction made, Barclays PLC holds 77,196 shares of BTMD stock, worth $510,265. This represents 0.0% of its overall portfolio holdings.

Number of Shares
77,196
Previous 77,196 -0.0%
Holding current value
$510,265
Previous $432,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024

BUY
$5.33 - $8.36 $141,298 - $221,623
26,510 Added 52.3%
77,196 $432,000
Q2 2024

Aug 14, 2024

BUY
$5.44 - $7.47 $111,568 - $153,202
20,509 Added 67.96%
50,686 $379,000
Q1 2024

May 15, 2024

SELL
$3.79 - $6.91 $35,353 - $64,456
-9,328 Reduced 23.61%
30,177 $175,000
Q4 2023

Feb 15, 2024

BUY
$4.43 - $5.81 $66,516 - $87,237
15,015 Added 61.31%
39,505 $196,000
Q3 2023

Nov 07, 2023

BUY
$4.73 - $7.83 $102,494 - $169,668
21,669 Added 768.13%
24,490 $126,000
Q2 2023

Aug 03, 2023

BUY
$5.27 - $6.9 $14,866 - $19,464
2,821 New
2,821 $19,000

Others Institutions Holding BTMD

About biote Corp.


  • Ticker BTMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Care Facilities
  • Shares Outstandng 7,574,270
  • Market Cap $50.1M
  • Description
  • biote Corp. operates in medical practice-building business within the hormone optimization space. The company offers a platform for Biote-certified practitioners to optimize imbalances in their patient's hormone, vitamin, and mineral levels, as well as prescribe bioidentical hormone therapies and recommend dietary supplements. It also sells Biot...
More about BTMD
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.